[EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE PROGÉNITEUR HÉMATOPOÏÉTIQUE KINASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
摘要:
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
[EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE PROGÉNITEUR HÉMATOPOÏÉTIQUE KINASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
摘要:
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R
1
is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R
2
is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
Compounds of formula (I), and salts and pro-drugs thereof:
wherein for example R
1
is optionally substituted aryl or heteroaryl;
Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain;
R
2
is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group;
are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
[EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE PROGÉNITEUR HÉMATOPOÏÉTIQUE KINASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
申请人:[en]NURIX THERAPEUTICS, INC.
公开号:WO2023086399A1
公开(公告)日:2023-05-19
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.